|Bid||0.1700 x N/A|
|Ask||0.1750 x N/A|
|Day's Range||0.1600 - 0.1800|
|52 Week Range||0.0200 - 0.2700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.Philip Young, CEO and Director of Lobe, stated, "We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research ...
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at "The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference", a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.As a ...
BALTIMORE, MD / ACCESSWIRE / February 24, 2021 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Lobe Sciences Ltd. Lobe Sciences is a life sciences company focused on psychedelic medicines.